Diminishing blood loss during operation for burns.

What Was Tested

The paper reports a study of Deamino Arginine Vasopressin, published as a randomized controlled trial.

The current placebo-controlled, randomized clinical trial was done to determine the effect of preoperative 1-desamino-8-D-arginine vasopressin (DDAVP) infusion on blood loss in patients undergoing burn débridement and grafting, a patient population in which extreme blood loss is a frequent occurrence.

Why It Was Studied

Eleven patients undergoing 22 surgical procedures completed the study protocol--mean age was 33 years (range of 12 to 70 years), mean burn size was 53 percent body surface area (BSA) (range of 17 to 92 percent) and mean area débrided and grafted was 3,935 centimeters squared (range of 848 to 8,134) or 21.1 percent (range of 4.0 to 43.5 percent) BSA.

The control group received placebo in a similar manner.

Who Took Part

The age groups tagged for this paper are children, teenagers, adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

In design terms this was a randomized and placebo-controlled study.

Because people in this Deamino Arginine Vasopressin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

A placebo (an inactive look-alike) gave the Deamino Arginine Vasopressin group a baseline to be compared against.

What Was Measured

Topics PubMed links to this paper include Blood Loss, Surgical, Blood Volume, Burns, Deamino Arginine Vasopressin, Hemostasis, Surgical and Intraoperative Period.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Deamino Arginine Vasopressin.

The publication is from 1993 (Surgery, gynecology & obstetrics), a journal based in United States.

More context: all human trials.